Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential TherapyHidekatsu Kuroda, Yasuhiro Takikawa, Takayoshi Oikawa et al.|Liver Cancer|2022Cited by 45
Influence of skeletal muscle volume loss during lenvatinib treatment on prognosis in unresectable hepatocellular carcinoma: a multicenter study in Tohoku, JapanMasashi Fujita, Hiromasa Ohira, Kazumichi Abe et al.|Scientific Reports|2022Cited by 17
Tuesday, 28 August 2012M. C. Ostojic, P. Deedwania, D. A. Demicco et al.|European Heart Journal|2012Cited by 2